Individualized Headache Management Approach Preferred for Children With Cerebrovascular Disease, Review Suggests

A review recently published in Headache suggested that headache is a common but potentially challenging complication in children who have experienced a stroke or have cerebrovascular disease, as commonly used headache treatments may carry additional cerebrovascular risks in this population.¹

The review synthesized available evidence on pharmacologic and nonpharmacologic approaches to headache management in pediatric patients with prior stroke or underlying cerebrovascular lesions. At the conclusion of the review, the study authors emphasized that although several commonly used headache therapies may be effective, their vasoactive or blood pressure–modulating properties can create theoretical concerns in patients with impaired cerebral perfusion, fragile collateral circulation, or a propensity for hemorrhage.

Led by Allison C. Hyland, MD, and colleagues, the review assessed headache medication classes in the context of various neurovascular conditions. Pediatric and adolescent studies were prioritized when available, although the authors incorporated evidence from adult populations when pediatric data were lacking.

The conditions included were ischemic and hemorrhagic stroke, arteriovenous malformations (AVMs), arteriovenous fistulas (AVFs), cerebral cavernous malformations (CCMs), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), Moyamoya vasculopathy, reversible cerebral vasoconstriction syndrome (RCVS), Sturge-Weber syndrome (SWS), and vascular insufficiency or stenosis.

Headache After Stroke Presents a Treatment Challenge

Across stroke etiologies, chronic headache has been reported in approximately 12% to 57% of patients. In ischemic stroke specifically, headache has been reported in 55% to 100% of patients with extracranial cervical artery dissection, 15% to 41% of those with large-artery atherosclerosis, 13% to 33% with small-vessel disease, and 9% to 39% with cardioembolic stroke. Persistent headache lasting longer than 3 months has been reported in approximately 12% of patients.¹

The review noted that persistent poststroke headache may be more common among younger patients and females, as well as individuals with pre-existing headache disorders, poststroke fatigue, or depression. Headaches following stroke have more commonly been characterized as tension-type rather than migraine.

The treatment challenge stems in part from the vascular effects of several standard headache therapies. Triptans and ergots have vasoconstrictive properties and remain generally contraindicated or strongly cautioned in patients with a history of ischemic or hemorrhagic stroke. Dihydroergotamine (DHE) is similarly contraindicated following ischemic stroke because of theoretical risks associated with its vasoactive effects.

The review also highlighted an important distinction among vascular disorders. In Moyamoya vasculopathy, for example, progressive stenosis of the terminal internal carotid artery and proximal middle and/or anterior cerebral arteries can leave patients dependent on fragile collateral vessels. Headache occurs in up to 50% of patients with Moyamoya and may reflect chronic cerebral hypoperfusion. Because of the potential for further compromising cerebral blood flow, triptans and ergots should generally be avoided.

Blood pressure management likewise requires an individualized approach. Although beta-blockers, calcium channel blockers, and angiotensin receptor blockers may be useful in some patients with stroke or other vascular conditions, antihypertensive therapy can be problematic in disorders such as Moyamoya, where excessive reductions in blood pressure may contribute to watershed ischemia. The authors noted that some calcium channel blockers, including verapamil and nicardipine, have demonstrated potential benefit for headache in Moyamoya, but concerns regarding hypotension and reduced cerebral perfusion remain.

CGRP Therapies Add Another Layer of Complexity

The review also examined the growing use of calcitonin gene-related peptide (CGRP)–targeting therapies for migraine. Although these agents are not formally contraindicated in patients with a history of ischemic stroke, the authors identified a theoretical concern because CGRP contributes to vasodilation and may help maintain cerebral perfusion under ischemic conditions.

Preclinical findings have heightened those concerns. In mouse models of middle cerebral artery occlusion, gepants including olcegepant and rimegepant were associated with increased ischemic lesion size, reduced collateral flow, decreased reperfusion success, and worse neurologic outcomes.¹

Similar considerations apply to patients with flow-dependent vascular disorders. In Moyamoya, for example, CGRP antagonists are generally avoided because of concerns that blocking CGRP-mediated vasodilation could impair compensatory collateral circulation.

At the same time, the evidence is not uniformly unfavorable. In CADASIL, which is associated with migraine in approximately 55% to 75% of cases, newer observational data suggested that triptans may be effective without complications in some patients despite their traditional contraindication. The review noted that 46% of patients in one study reported effective triptan use without complications.

Overall, these findings underscored the authors' broader point: treatment decisions cannot necessarily be based solely on the presence of a cerebrovascular diagnosis. The specific lesion, vascular physiology, blood pressure requirements, and dependence on collateral flow may all influence the risk-benefit profile of an individual therapy.

Nonpharmacologic Strategies May Offer an Alternative

Given the vascular considerations associated with some medications, nonpharmacologic approaches may represent particularly attractive options for children with cerebrovascular disease. The review identified cognitive behavioral therapy, biofeedback, relaxation-based approaches, physical therapy, and noninvasive brain stimulation as potential strategies.

Neuromodulatory approaches may be particularly appealing because they can provide acute or preventive headache treatment without directly altering cerebrovascular tone or systemic hemodynamics. However, the authors noted that the evaluation of these modalities was beyond the scope of the review and that evidence specifically in vascular-associated pediatric headache remains limited.¹

The review also found that treating the underlying vascular lesion itself can improve headache in some patients. For AVMs, surgical approaches including embolization, radiosurgery, microsurgical resection, or multimodal treatment have been associated with headache improvement. In one retrospective analysis, Gamma Knife stereotactic radiosurgery reduced headache severity by 44% and headache frequency by 53%.

Similarly, treatment of AVFs may be central to headache management. Endovascular therapy is recommended as first-line treatment for most intracranial dural AVFs, and embolization has been associated with resolution of headaches in multiple reports, including a case involving a 6-year-old child with recurrent right-sided migrainous headaches.

In SWS, a condition in which headaches can begin during childhood and occur alongside vascular and neurologic complications, the review identified some pediatric-specific evidence supporting flunarizine. In a pediatric cohort, the medication reduced headache severity, frequency, and duration, with headache resolution occurring within the first month in 5 of 20 patients. However, the authors emphasized the importance of avoiding abrupt blood pressure changes given altered cerebral flow associated with leptomeningeal angiomatosis.

Evidence Remains Limited in Pediatric Populations

Despite the breadth of conditions and therapies examined, the authors stressed that the evidence base remains a major limitation. Much of the available research regarding medication efficacy and safety comes from adult populations, with pediatric-specific clinical trials particularly scarce. As a result, treatment recommendations often rely on extrapolation from adult studies, small case series, individual reports, animal models, or pathophysiologic reasoning.¹

The authors therefore advocated for individualized treatment based on the underlying cerebrovascular lesion and its hemodynamic characteristics. When evidence is limited, they recommend selecting therapies without clear physiologic contraindications while closely monitoring patients for worsening headache frequency or severity.

Investigators note that future research should include standardized characterization of vascular-associated headache, longitudinal assessment of treatment exposure and outcomes, and integration of imaging and physiologic biomarkers to better define mechanisms underlying headache in these patients. Prospective studies specifically enrolling pediatric patients will also be needed to establish evidence-based treatment strategies that balance headache control with cerebrovascular safety.

For clinicians caring for children with stroke or cerebrovascular lesions, the review ultimately frames headache treatment as a balance between controlling symptoms and preserving cerebral perfusion. Rather than applying a uniform migraine treatment strategy, clinicians may need to consider the underlying vascular anatomy, hemodynamic stability, and degree of collateral dependence before selecting an acute or preventive therapy.

REFERENCES
1. Hyland AC, Belfer SJ, Fox CK, et al. Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: a narrative review. Headache. Published online August 11, 2026. doi:10.1111/head.70159